2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. HMG-CoA Reductase (HMGCR)

HMG-CoA Reductase (HMGCR)

HMG-CoA Reductase (HMGCR)

Related Products

PDF 0.82 MB

HMG-CoA Reductase (HMGCR) is the rate-limiting enzyme for cholesterol synthesis in the conversion of HMG-CoA to mevalonate. HMGCR is found in eukaryotes and prokaryotes. The phylogenetic analysis has revealed two classes of HMG-CoA reductase, the Class I enzymes of eukaryotes and some archaea and the Class II enzymes of eubacteria and certain other archaea.

Both in eukaryotes and in archaebacteria the enzyme HMGCR is known to catalyze an early reaction unique to isoprenoid biosynthesis. In humans, the HMG-CoA reductase reaction is rate-limiting for the biosynthesis of cholesterol and therefore constitutes a prime target of drugs that reduce serum cholesterol levels.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-110231
    Simvastatin-d6
    		Inhibitor 99.6%
    Simvastatin-d6 (MK 733-d6) is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    Simvastatin-d<sub>6</sub>
  • HY-121795
    Pravastatin lactone
    		Inhibitor 99.20%
    Pravastatin lactone is a potent HMG-CoA inhibitor. Pravastatin Lactone is a metabolite of pravastatin. Pravastatin lactone reduces blood cholesterol levels by inhibiting cholesterol synthesis.
    Pravastatin lactone
  • HY-14664F
    (3R,5S)-Fluvastatin sodium
    		99.18%
    (3R,5S)-Fluvastatin ((3R,5S)-XU 62-320) sodium is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
    (3R,5S)-Fluvastatin sodium
  • HY-106281A
    Bemfivastatin hemicalcium
    		Inhibitor 98.00%
    Bemfivastatin (PPD 10558) hemicalcium is an orally active lipid-lowering agent and HMG-CoA reductase inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extracts. Bemfivastatin hemicalcium has no-observed adverse effect levels (NOAEL) with dosages of ≥320 mg/kg/d (rat developmental toxicity), ≥12.5 mg/kg/d (rabbit maternal toxicity), ≥25 mg/kg/d (rabbit developmental toxicity), respectively. Bemfivastatin hemicalcium can be used in the study of statin-related hypercholesterolemic myalgia in statin-intolerant patients.
    Bemfivastatin hemicalcium
  • HY-B0589E
    Atorvastatin hemicalcium trihydrate
    		Inhibitor 99.64%
    Atorvastatin hemicalcium trihydrate is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin hemicalcium trihydrate
  • HY-B0589S1
    Atorvastatin-d5 sodium
    		Inhibitor
    Atorvastatin-d5 (sodium) is the deuterium labeled Atorvastatin sodium. Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin-d<sub>5</sub> sodium
  • HY-17504A
    Rosuvastatin
    		Inhibitor
    Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    Rosuvastatin
  • HY-17502S1
    Simvastatin-d3
    		98.61%
    Simvastatin-d3 is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    Simvastatin-d<sub>3</sub>
  • HY-122439
    Lovastatin acid
    		Inhibitor
    Lovastatin acid (Mevinolinic acid), an active metabolite of Lovastatin, is a potent competitive HMG-CoA reductase inhibitor with a Ki of 0.6 nM.
    Lovastatin acid
  • HY-N11637
    Ganoderenic acid K
    		Inhibitor 99.64%
    Ganoderenic acid K is a natural product, that can be isolated from fruiting bodies of Ganoderma lucidum. Ganoderenic acid K shows strong inhibitory activity against HMG-CoA reductase (HMGCR) with IC50 of 16.5 μM.
    Ganoderenic acid K
  • HY-135383
    (3S,5S)-Pitavastatin calcium
    		Control 99.94%
    (3S,5S)-Pitavastatin calcium is the 3-epimer of Pitavastatin Calcium (HY-B0144). Pitavastatin Calcium is a potent HMG-CoA reductase inhibitor that can be used for the study of cardiovascular disease.
    (3S,5S)-Pitavastatin calcium
  • HY-B0144AS1
    Pitavastatin-d5 sodium
    		Inhibitor 99.53%
    Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
    Pitavastatin-d<sub>5</sub> sodium
  • HY-19671
    Apomine
    		Inhibitor 99.67%
    Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer.
    Apomine
  • HY-B0144AS
    Pitavastatin-d4
    		Inhibitor 99.09%
    Pitavastatin-d4 is deuterium labeled Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.
    Pitavastatin-d<sub>4</sub>
  • HY-14664C
    (3S,5R)-Fluvastatin sodium
    		Inhibitor 98.16%
    (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer of Fluvastatin. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
    (3S,5R)-Fluvastatin sodium
  • HY-17504S
    Rosuvastatin-d6 calcium
    		Inhibitor 98.54%
    Rosuvastatin-d6 (calcium) is deuterium labeled Rosuvastatin.
    Rosuvastatin-d<sub>6</sub> calcium
  • HY-17504BS1
    Rosuvastatin-d6 sodium
    		Inhibitor 98.60%
    Rosuvastatin-d6 (sodium) is deuterium labeled Rosuvastatin.
    Rosuvastatin-d<sub>6</sub> sodium
  • HY-108257
    Atorvastatin sodium
    		Inhibitor 99.76%
    Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin sodium
  • HY-B1189S
    Meglutol-d3
    		98.04%
    Meglutol-d3 is the deuterium labeled Meglutol. Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.
    Meglutol-d<sub>3</sub>
  • HY-B0165
    Pravastatin
    		Inhibitor
    Pravastatin (CS-514) is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
    Pravastatin
Cat. No. Product Name / Synonyms Application Reactivity